4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Cue Biopharma, Inc. (CUE) operates in the Biotechnology industry and is headquartered in Boston, United States with about 29 employees. Its market capitalization is roughly $120 million. In the fiscal year ended 2025-12-31, CUE reported $28M in revenue and ($27M) in net income.
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Interactive charts & full statements → Open the CUE valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $28M | $9M | $6M | $1M | — |
| Operating Income (EBIT) | ($26M) | ($42M) | ($52M) | ($54M) | — |
| Net Income | ($27M) | ($41M) | ($51M) | ($53M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $6M | $22M | $2M | $3M | $0M | — |
| Operating Income (EBIT) | ($5M) | $2M | ($8M) | ($9M) | ($12M) | — |
| Net Income | ($5M) | $2M | ($7M) | ($8M) | ($12M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $42M | $32M | $62M | $91M | — |
| Total Liabilities | $16M | $15M | $24M | $26M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CUE viewer.
About TickerBase · Data methodology & sources